Dalteparin

Brand names: Fragmin · Active ingredient: Dalteparin Sodium

In short: FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy . FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE

Forms & strengthsFRAGMIN (dalteparin sodium) injection is a sterile, aqueous, clear, colorless or straw-colored solution for injection, available in the following dosage forms and strengths: •Injection: 2,500 units/ 0.2 mL, 5,000 units/ 0.2 mL, 7,500 units/ 0.3 mL, 12,500 …
LabelPfizer Laboratories Div Pfizer Inc
Label updatedOct 02, 2025

What is Dalteparin used for?

FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy .

FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):

•In patients undergoing hip replacement surgery ;

•In patients undergoing abdominal surgery who are at risk for thromboembolic complications ;

•In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness .

FRAGMIN is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal DVT and/or PE), to reduce the recurrence of VTE in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months .

FRAGMIN is indicated for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks).

FRAGMIN is not indicated for the acute treatment of VTE.

âš  Boxed warning (FDA's strongest warning)

Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

•

Use of indwelling epidural catheters

•

Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.

•

A history of traumatic or repeated epidural or spinal punctures

•

A history of spinal deformity or spinal surgery

•

Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis .

Dalteparin dosage

In patients with unstable angina or non-Q-wave myocardial infarction, the recommended dose of FRAGMIN Injection is 120 units/kg of body weight, but not more than 10,000 units, subcutaneously every 12 hours with concurrent oral aspirin (75 mg to 165 mg once daily) therapy. Treatment should be continued until the patient is clinically stabilized. The usual duration of administration is 5 days to 8 days. Concurrent aspirin therapy is recommended except when contraindicated.

Table 1 lists the volume of FRAGMIN in mL (based on the 3.8 mL multiple-dose vial 25,000 units/mL) and quantity of FRAGMIN in units, to be administered for a range of patient weights.

Table 1

Quantity and Volume of FRAGMIN to be Administered by Patient Weight

Patient weight (kg) | <50 kg | 50 kg to 59 kg | 60 kg to 69 kg | 70 kg to 79 kg | 80 kg to 89 kg | ≥90 kg

Quantity of FRAGMIN (units) | 5,500 units | 6,500 units | 7,500 units | 9,000 units | 10,000 units | 10,000 units

Volume of FRAGMIN (mL)95,000 units / 3.8 mL | 0.22 mL | 0.26 mL | 0.3 mL | 0.36 mL | 0.4 mL | 0.4 mL

Prophylaxis of VTE Following Hip Replacement Surgery: Table 2 presents the dosing options for patients undergoing hip replacement surgery. The usual duration of administration is 5 days to 10 days after surgery; up to 14 days of treatment with FRAGMIN have been well tolerated in clinical trials.

Table 2

Dosing Options for Patients Undergoing Hip Replacement Surgery

Timing of First Dose of FRAGMIN | Dose of FRAGMIN to be Given Subcutaneously

10 Hours to 14 Hours Before Surgery | Within 2 Hours Before Surgery | 4 Hours to 8 Hours After SurgeryOr later, if hemostasis has not been achieved. | Postoperative PeriodUp to 14 days of treatment was well tolerated in controlled clinical trials, where the usual duration of treatment was 5 days to 10 days postoperatively.

Postoperative Start | --- | --- | 2,500 unitsAllow a minimum of 6 hours between this dose and the dose to be given on Postoperative Day 1. Adjust the timing of the dose on Postoperative Day 1 accordingly. | 5,000 units once daily

Preoperative Start - Day of Surgery | --- | 2,500 units | 2,500 units | 5,000 units once daily

Preoperative Start - Evening Before SurgeryAllow approximately 24 hours between doses. | 5,000 units | --- | 5,000 units | 5,000 units once daily

Abdominal Surgery: In patients undergoing abdominal surgery with a risk of thromboembolic complications, the recommended dose of FRAGMIN is 2,500 units administered by subcutaneous injection once daily, starting 1 hour to 2 hours prior to surgery and repeated once daily postoperatively. The usual duration of administration is 5 days to 10 days. …

How to take Dalteparin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Risk of Hemorrhage including Spinal/Epidural Hematomas

If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, inform the patients to watch for signs and symptoms of spinal or epidural hematoma, such as tingling, numbness (especially in the lower limbs) and muscular weakness. If any of these symptoms occur the patient should contact his or her physician immediately.

Additionally, the use of aspirin and other NSAIDs may enhance the risk of hemorrhage. Discontinue their use prior to FRAGMIN therapy whenever possible; if co-administration is essential, the patient's clinical and laboratory status should be closely monitored .

Inform Patients:

•of the instructions for injecting FRAGMIN if their therapy is to continue after discharge from the hospitals.

•it may take them longer than usual to stop bleeding.

•they may bruise and/or bleed more easily when they are treated with FRAGMIN. …

Warnings & precautions

Do not take this medicine if: FRAGMIN is contraindicated in:

•Patients with active major bleeding.

•Patients with a history of heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombosis.

•Patients with prior hypersensitivity to dalteparin sodium (e.g., pruritis, rash, anaphylactic reactions) .

•Patients undergoing Epidural/Neuraxial anesthesia, do not administer FRAGMIN ;

oAs a treatment for unstable angina and non-Q-wave MI.

oFor prolonged VTE prophylaxis.

•Patients with prior hypersensitivity to heparin or pork products.

Spinal or epidural hemorrhage and subsequent hematomas can occur with the associated use of low molecular weight heparins or heparinoids and neuraxial (spinal/epidural) anesthesia or spinal puncture. The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or spinal deformity .

To reduce the potential risk of bleeding associated with the concurrent use of FRAGMIN and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of FRAGMIN .

Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of FRAGMIN is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. No additional hemostasis-altering medications should be administered due to the additive effects.

Patients on preoperative FRAGMIN thromboprophylaxis can be assumed to have altered coagulation. The first postoperative FRAGMIN thromboprophylaxis dose (2,500 units) should be administered 6 hours to 8 hours postoperatively. …

Dalteparin side effects

The following clinically significant adverse reactions are described in more detail in other sections of the prescribing information.

•Risk of Hemorrhage including Spinal/Epidural Hematomas

•Thrombocytopenia

•Benzyl Alcohol Preservative Risk to Premature Infants

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not accurately reflect the rates observed in practice.

Hemorrhage

The most commonly reported adverse reactions are hematoma at the injection site and hemorrhagic complications. The risk for bleeding varies with the indication and may increase with higher doses.

Unstable Angina and Non-Q-Wave Myocardial Infarction

Table 7 summarizes major bleeding reactions that occurred with FRAGMIN, heparin, and placebo in clinical trials of unstable angina and non-Q-wave myocardial infarction.

Table 7

Major Bleeding Reactions in Unstable Angina and Non-Q-Wave Myocardial Infarction

Indication | Dosing Regimen

Unstable Angina and Non-Q-Wave MI | FRAGMIN

120 units/kg/12 hours subcutaneousTreatment was administered for 5 days to 8 days.

n (%) | Heparin

Heparin intravenous infusion for at least 48 hours, APTT 1.5 to 2 times control, then 12,500 units subcutaneously every 12 hours for 5 days to 8 days. …

Drug interactions

The use of FRAGMIN in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents may increase the risk of bleeding .

About this medicine

FRAGMIN Injection (dalteparin sodium injection) is a sterile, low molecular weight heparin. It is available in single-dose, prefilled syringes preassembled with a needle guard device, and multiple-dose vials. With reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard, each syringe contains either 2,500 units, 5,000 units, 7,500 units, 10,000 units, 12,500 units, 15,000 units or 18,000 anti-Xa international units (units), equivalent to 16 mg, 32 mg, 48 mg, 64 mg, 80 mg, 96 mg or 115.2 mg dalteparin sodium, respectively. Each multiple-dose vial contains 25,000 anti-Xa units per 1 mL (equivalent to 160 mg dalteparin sodium), for a total of 95,000 anti-Xa units per vial. Each single-dose vial contains 2,500 anti-Xa units per 1 mL (equivalent to 16 mg dalteparin sodium) for a total of 10,000 anti-Xa units per vial.

Each prefilled syringe also contains Water for Injection and sodium chloride, when required, to maintain physiologic ionic strength. The prefilled syringes are preservative-free. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 23527b8b-9b28-4e6d-9751-33b143975ac7. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol